Tonix Pharmaceuticals Holding Corp. earnings per share and revenue
On Nov 10, 2025, TNXP reported earnings of -3.59 USD per share (EPS) for Q3 25, beating the estimate of -3.65 USD, resulting in a 1.82% surprise. Revenue reached 3.29 million, compared to an expected 3.16 million, with a 4.05% difference. The market reacted with a +4.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -3.25 USD, with revenue projected to reach 3.03 million USD, implying an decrease of -9.47% EPS, and decrease of -8.02% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Tonix Pharmaceuticals Holding Corp.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Tonix Pharmaceuticals Holding Corp. reported EPS of -$3.59, beating estimates by 1.82%, and revenue of $3.29M, 4.05% above expectations.
How did the market react to Tonix Pharmaceuticals Holding Corp.'s Q3 2025 earnings?
The stock price moved up 4.1%, changed from $16.84 before the earnings release to $17.53 the day after.
When is Tonix Pharmaceuticals Holding Corp. expected to report next?
The next earning report is scheduled for Mar 16, 2026.
What are the forecasts for Tonix Pharmaceuticals Holding Corp.'s next earnings report?
Based on 5
analysts, Tonix Pharmaceuticals Holding Corp. is expected to report EPS of -$3.25 and revenue of $3.03M for Q4 2025.